EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

CD45 limits early Natural Killer cell development

Lizeth G Meza Guzman iD, Craig D Hyland, Grace M Bidgood, Evelyn Leong, Zihan Shen, Wilford Goh, Jai Rautela, James E Vince, Sandra E Nicholson, Nicholas D Huntington iD

Immunology & Cell Biology · 2024

DOI: 10.1111/imcb.12701 ↗

At a glance

Journal article in Immunology & Cell Biology, 2024. Written by Lizeth G Meza Guzman and 9 co-authors. Institution: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. Major MEDLINE topics: Killer Cells, Natural, Neoplasms. Cited 3 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The clinical development of Natural Killer (NK) cell‐mediated immunotherapy marks a milestone in the development of new cancer therapies and has gained traction due to the intrinsic ability of the NK cell to target and kill tumor cells. To fully harness the tumor killing ability of NK cells, we need to improve NK cell persistence and to overcome suppression of NK cell activation in the tumor microenvironment. The trans‐membrane, protein tyrosine phosphatase CD45, regulates NK cell homeostasis, with the genetic loss of CD45 in mice resulting in increased numbers of mature NK cells. This suggests that CD45‐deficient NK cells might display enhanced persistence following adoptive transfer. However, we demonstrate here that adoptive transfer of CD45‐deficiency did not enhance NK cell persistence in mice, and instead, the homeostatic disturbance of NK cells in CD45‐deficient mice stemmed from a developmental defect in the progenitor population. The enhanced maturation within the CD45‐deficient NK cell compartment was intrinsic to the NK cell lineage, and independent of the developmental defect. CD45 is not a conventional immune checkpoint candidate, as systemic loss is detrimental to T and B cell development, compromising the adaptive immune system. Nonetheless, this study suggests that inhibition of CD45 in progenitor or stem cell populations may improve the yield of in vitro generated NK cells for adoptive therapy.

Subjects

MeSH terms (MEDLINE)

Killer Cells, NaturalNeoplasmsAnimalsMiceImmunotherapyImmunotherapy, AdoptiveTumor MicroenvironmentLeukocyte Common Antigens

Author keywords

CD45NK progenitorNatural Killer cellshematopoiesislymphocytes

Substances

Ptprc protein, mouseLeukocyte Common Antigens

Authors and institutions

  • The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.

ORCID profiles: Lizeth G Meza Guzman, Nicholas D Huntington

Funding

  • National Health and Medical Research Council

Cite

APA

Meza Guzman, L. G., Hyland, C. D., Bidgood, G. M., Leong, E., Shen, Z., Goh, W., Rautela, J., Vince, J. E., Nicholson, S. E., & Huntington, N. D. (2024). CD45 limits early Natural Killer cell development. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12701

Vancouver

Meza Guzman LG, Hyland CD, Bidgood GM, Leong E, Shen Z, Goh W, et al. CD45 limits early Natural Killer cell development. Immunology & Cell Biology. 2024. doi:10.1111/imcb.12701

BibTeX
@article{MezaGuzman2024,
  author = {Meza Guzman, Lizeth G and Hyland, Craig D and Bidgood, Grace M and Leong, Evelyn and Shen, Zihan and Goh, Wilford and Rautela, Jai and Vince, James E and Nicholson, Sandra E and Huntington, Nicholas D},
  title = {CD45 limits early Natural Killer cell development},
  journal = {Immunology & Cell Biology},
  year = {2024},
  doi = {10.1111/imcb.12701}
}
Start for free →